The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
04
2021
accepted:
15
04
2022
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Toll-like receptors (TLRs) play a pivotal role in the immune system and carcinogenesis. There is no research on TLR expression and association with survival among preoperatively treated pancreatic cancer patients. We studied the expression intensity and prognostic value of TLRs in pancreatic cancer patients treated with neoadjuvant therapy (NAT) and compared the results to patients undergoing upfront surgery (US). Between 2000 and 2015, 71 borderline resectable patients were treated with NAT and surgery and 145 resectable patients underwent upfront surgery at Helsinki University Hospital, Finland. We immunostained TLRs 1-5, 7, and 9 on sections of tissue-microarray. We classified TLR expression as 0 (negative), 1 (mild), 2 (moderate), or 3 (strong) and divided into high (2-3) and low (0-1) expression for statistical purposes. Among TLRs 1, 3, and 9 (TLR1 81% vs 70%, p = 0.008; TLR3 92% vs 68%, p = 0.001; TLR9 cytoplasmic 83% vs 42%, p<0.001; TLR9 membranous 53% vs 25%, p = 0.002) NAT patients exhibited a higher immunopositivity score more frequently than patients undergoing upfront surgery. Among NAT patients, a high expression of TLR1 [Hazards ratio (HR) 0.48, p<0.05] associated with a longer postoperative survival, whereas among US patients, high expression of TLR5 (HR 0.64, p<0.05), TLR7 (HR 0.59, p<0.01, and both TLR7 and TLR9 (HR 0.5, p<0.01) predicted a favorable postoperative outcome in separate analysis adjusted for background variables. We found higher immunopositive intensities among TLRs 1, 3, and 9 in NAT patients. A high TLR1 expression associated with a longer survival among NAT patients, however, among US patients, high expression intensity of TLR5 and TLR7 predicted a favorable postoperative outcome in the adjusted analysis.
Identifiants
pubmed: 35536778
doi: 10.1371/journal.pone.0267792
pii: PONE-D-21-14223
pmc: PMC9089880
doi:
Substances chimiques
Toll-Like Receptor 1
0
Toll-Like Receptor 5
0
Toll-Like Receptor 7
0
Toll-Like Receptor 9
0
Toll-Like Receptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0267792Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Exp Med. 2012 Aug 27;209(9):1671-87
pubmed: 22908323
Virchows Arch. 2017 Apr;470(4):401-410
pubmed: 28191612
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Nat Rev Immunol. 2007 May;7(5):353-64
pubmed: 17457343
Diabetes Care. 2010 Apr;33(4):861-8
pubmed: 20067962
Int J Oncol. 2015 Sep;47(3):857-66
pubmed: 26134824
Tohoku J Exp Med. 2009 Mar;217(3):175-84
pubmed: 19282652
Acta Oncol. 2018 Jun;57(6):799-806
pubmed: 29241394
Surg Oncol. 2002 May;10(4):153-69
pubmed: 12020670
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Cancer Lett. 2015 Dec 28;369(2):298-306
pubmed: 26433159
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005
Tumour Biol. 2018 Sep;40(9):1010428318801188
pubmed: 30246618
Pancreatology. 2018 Jul;18(5):467-476
pubmed: 29843972
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Medicine (Baltimore). 2021 Jan 22;100(3):e24068
pubmed: 33546009
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Biochem Biophys Res Commun. 2009 Oct 30;388(4):621-5
pubmed: 19686699
APMIS. 2018 Nov;126(11):852-863
pubmed: 30357962
Ann Surg. 2019 Aug;270(2):340-347
pubmed: 29596120
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Invest. 2012 Nov;122(11):4118-29
pubmed: 23023703
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
Neoplasia. 2009 May;11(5):497-508
pubmed: 19412434
Oncoimmunology. 2013 Jan 1;2(1):e22567
pubmed: 23483804
Biochem Pharmacol. 2010 Sep 1;80(5):748-54
pubmed: 20510208
Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E740-7
pubmed: 17090751
J Exp Med. 2015 Nov 16;212(12):2077-94
pubmed: 26481685
Mediators Inflamm. 2010;2010:
pubmed: 20706656
Front Immunol. 2014 Dec 15;5:638
pubmed: 25566251
PLoS One. 2014 May 02;9(5):e96565
pubmed: 24794217
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14
pubmed: 19685283
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
J Gastroenterol. 2009;44(4):249-60
pubmed: 19271115
World J Gastroenterol. 2010 Jun 21;16(23):2881-8
pubmed: 20556833
Immunobiology. 2017 Jan;222(1):89-100
pubmed: 27349597
Gastroenterology. 2011 Dec;141(6):2154-65
pubmed: 21920464
PLoS One. 2016 Sep 15;11(9):e0163064
pubmed: 27632196
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Lancet Infect Dis. 2011 Sep;11(9):702-12
pubmed: 21719349
Cancer Res. 2009 Nov 15;69(22):8710-7
pubmed: 19887600
Int Rev Immunol. 2014 Nov-Dec;33(6):443-53
pubmed: 24911430
World J Gastroenterol. 2014 May 21;20(19):5808-17
pubmed: 24914341
Lancet Oncol. 2012 Jul;13(7):e301-10
pubmed: 22748269
Int J Mol Sci. 2016 Dec 08;17(12):
pubmed: 27941651
Int J Surg. 2016 Oct;34:96-102
pubmed: 27573691
Gut. 2013 Jan;62(1):112-20
pubmed: 22466618
PLoS One. 2019 Jul 17;14(7):e0219245
pubmed: 31314777
Cancer Growth Metastasis. 2015 Jul 23;8:25-34
pubmed: 26279628
Gastroenterology. 2013 Jun;144(6):1230-40
pubmed: 23622132